» Articles » PMID: 26168997

Dosing Profile Profoundly Influences Nicotinic Acid's Ability to Improve Metabolic Control in Rats

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2015 Jul 15
PMID 26168997
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Acute nicotinic acid (NiAc) administration results in rapid reduction of plasma FFA concentrations. However, sustained NiAc exposure is associated with tolerance development resulting in return of FFA to pretreatment levels. The aim of this study was to determine whether a 12 h rectangular exposure profile (intermittent dose group) could avoid tolerance development and thereby reverse insulin resistance induced by lipid overload. FFA lowering was assessed in male Sprague Dawley (lean) and obese Zucker rats (obese) in response to a 5 h NiAc infusion, in either NiAc-naïve animals or after 5 days of continuous (24 h/day) or intermittent (12 h/day) NiAc dosing (via implantable, programmable minipump). We found that intermittent dosing over 5 days preserved NiAc-induced FFA lowering, comparable to dosing in NiAc-naïve animals. By contrast, following 5 days continuous administration, NiAc-induced FFA lowering was lost. The effect of intermittent NiAc infusion on insulin sensitivity was assessed in obese Zucker rats using hyperinsulinemic-isoglycemic clamps. The acute effect of NiAc to elevate glucose infusion rate (vs. saline control) was indeed preserved with intermittent dosing, while being lost upon continuous infusion. In conclusion, an intermittent but not continuous NiAc dosing strategy succeeded in retaining NiAc's ability to lower FFA and improve insulin sensitivity in obese Zucker rats.-Kroon, T., A. Kjellstedt, P. Thalén, J. Gabrielsson, and N. D. Oakes.

Citing Articles

The Role of GPR109a Signaling in Niacin Induced Effects on Fed and Fasted Hepatic Metabolism.

Geisler C, Miller K, Ghimire S, Renquist B Int J Mol Sci. 2021; 22(8).

PMID: 33924461 PMC: 8069761. DOI: 10.3390/ijms22084001.


Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics.

Morigny P, Boucher J, Arner P, Langin D Nat Rev Endocrinol. 2021; 17(5):276-295.

PMID: 33627836 DOI: 10.1038/s41574-021-00471-8.


Involvement of the metabolic sensor GPR81 in cardiovascular control.

Wallenius K, Thalen P, Bjorkman J, Johannesson P, Wiseman J, Bottcher G JCI Insight. 2017; 2(19).

PMID: 28978803 PMC: 5841867. DOI: 10.1172/jci.insight.92564.


Regulation of hepatic glucose metabolism in health and disease.

Petersen M, Vatner D, Shulman G Nat Rev Endocrinol. 2017; 13(10):572-587.

PMID: 28731034 PMC: 5777172. DOI: 10.1038/nrendo.2017.80.


Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments.

Andersson R, Kroon T, Almquist J, Jirstrand M, Oakes N, Evans N J Pharmacokinet Pharmacodyn. 2017; 44(3):203-222.

PMID: 28224315 PMC: 5424002. DOI: 10.1007/s10928-017-9512-6.


References
1.
Gabrielsson J, Green A . Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. J Pharmacol Exp Ther. 2009; 331(3):767-74. DOI: 10.1124/jpet.109.157172. View

2.
Eckel R, Grundy S, Zimmet P . The metabolic syndrome. Lancet. 2005; 365(9468):1415-28. DOI: 10.1016/S0140-6736(05)66378-7. View

3.
Kraegen E, Cooney G . Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol. 2008; 19(3):235-41. DOI: 10.1097/01.mol.0000319118.44995.9a. View

4.
Hara N, Yamada K, Shibata T, Osago H, Hashimoto T, Tsuchiya M . Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J Biol Chem. 2007; 282(34):24574-82. DOI: 10.1074/jbc.M610357200. View

5.
Miettinen T, Taskinen M, PELKONEN R, NIKKILA E . Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. Acta Med Scand. 1969; 186(4):247-53. DOI: 10.1111/j.0954-6820.1969.tb01473.x. View